Apologies if this has been posted before, but I don't think i've seen it on HC. It's from April this year.
https://www.delveinsight.com/blog/knee-osteoarthritis-pipeline-therapies
They reckon Zilosul will be making around US$850m in sales in the 7MM (7 major markets: US, France, Germany, UK, Italy, Spain and Japan) by 2032. Personally, I think that figure is very low, but I suppose it's generally encouraging to see some analysis which includes Zilosul as part of the OA treatment landscape a decade from now - and obviously it's an article rather than any deep-dive analysis, so we can take it with a large pinch of salt.
Competition???, page-7
-
- There are more pages in this discussion • 62 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
23.5¢ |
Change
0.005(2.17%) |
Mkt cap ! $82.20M | |||
| Open | High | Low | Value | Volume |
| 23.5¢ | 23.5¢ | 23.0¢ | $85.35K | 365.1K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 280011 | 23.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 24.0¢ | 44703 | 3 |
View Market Depth
| Last trade - 16.10pm 06/09/2024 (20 minute delay) ? |
| PAR (ASX) Chart |